Scott A. Beardsley

JPMorgan Securities LLC (JPMS) is a securities brokerage firm headquartered in New York City. The firm was founded in 1985 and is a subsidiary of JPMorgan Broker-Dealer Holdings, Inc., ultimately held by JPMorgan Chase & Co., Inc. (NYSE: JPM). JPMS provides research on fixed income, credit, derivatives, emerging markets, foreign exchange, structured finance, technical analysis and bond indices. Their equity analysts cover equities throughout North America, EMEA, Asia/Pacific and the emerging markets. The firm's fixed income team formulates trading and portfolio recommendations for investors in global bonds and other fixed-income markets based on valuations, analytics and market dynamics.

Piper Jaffray Cos. is an investment bank and asset management firm, which engages in the provision of equity and debt capital markets products; public finance services; financial advisory services; equity research and institutional brokerage; fixed income institutional brokerage; and asset management services. It operates through Capital Markets and Asset Management segment. The Capital Markets segment focuses on investment banking and institutional sales, trading and research services for various equity and fixed income products. The Asset Management segment gives traditional asset management business and seed investments in registered and private funds. The company was founded in 1895 and is headquartered in Minneapolis, MN.

Aerocrine AB operates as a specialty pharmaceutical company focused on respiratory disease. The company was founded by Lars E. Gustafsson, Jon Lundberg, Kjell Alving, and Eddie Weitzberg in November 1997 and is headquartered in Uppsala, Sweden.

Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden.

Unchained Labs designs, develops, and manufactures tools and devices for biologics research. It sells its products to biopharma and academic customers. The company was founded by Timothy A. Harkness in January 2015 and is headquartered in Pleasanton, CA.

Anthos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes innovative therapies for high-risk cardiovascular patients. It offers MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. The company was founded by Paris Panayiotopoulos, Ari Brettman and Jonathan E. Freeman in 2018 and is headquartered in Cambridge, MA.